Gold+
Recently, various methods have been developed in cancer treatment, especially the interest in immunotherapy has been increasing as well. At the same time, the importance of chemotherapy, which is the basis of cancer treatment, cannot be overlooked.
In this regard, we would like to share the long-term contributions of Sanofi Oncology to various type of cancers and the latest trend of treatment sequence in chemotherapy, focusing on CRC.
| Address | 235 Banpo-daero. Seocho-gu. Seoul, Korea Zip code : 06578 | ||
|---|---|---|---|
| Telephone | +82-2-2136-9016 | Fax | none |
| Website | https://www.sanofi.com | MyoungSoo.Shin@sanofi.com | |
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi-aventis Korea has maintained its certification as Family Friendly Company since 2013 and its accreditation as Innovative Pharmaceutical Company since 2014. We are in Korea committed to working with local pharmaceutical companies, bio-techs, clinical research centers as well as academia in Korea to bring innovation where high unmet patient needs exist.
ELOXATIN (oxaliplatin) is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: - First line treatment of metastatic colorectal cancer in combination with 5-fluorouracil and folinic acid(leucovorin) - Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor in combination with 5-fluorouracil and folinic acid(leucovorin) - Unresectable advanced or metastatic gastric cancer - In combination with capecitabine, adjuvant treatment of stageII, III gastric cancer
ZALTRAP (ziv-aflibercept), a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.
